Sequential treatment for high-risk triple-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new sequence of drugs (Sac-TMT followed by capecitabine) versus capecitabine alone for people with early-stage, high-risk triple-negative breast cancer who do not have BRCA mutations. It aims to see if the added treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with early-stage breast cancer that is triple-negative (meaning it tests negative for estrogen, progesterone, and HER2 receptors).
- You do not have a BRCA1 or BRCA2 gene mutation.
- You have either completed neoadjuvant (pre-surgery) chemotherapy and still had cancer in the lymph nodes, or you had surgery and adjuvant (post-surgery) chemotherapy and had cancer in the lymph nodes.
- Your cancer has not spread to distant parts of the body.
- You have recovered from side effects of previous treatments and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
Hear when a new Adjuvant Drug Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.